US records 1,561 Coronavirus casualties in 24 hours

▴ us-records-1561-coronavirus-casualties-in-24-hours
Registers total 93,406 fatalities according to the real-time tally by Johns Hopkins University

The proliferating Coronavirus death across the United States recorded 1,561 casualties in the past 24 hours, registering a total of 93,406 fatalities according to the real-time tally by Johns Hopkins University.

The worst-hit country has the register ringing continuously with the total cases last confirmed to be 1,550,959, as reported by the Baltimore-based school

But there is a sign of hope that can contain the rise in virus infection as  Sorrento Therapeutics, announces its anti-SARS-CoV-2 antibody, STI-1499 that has exhibited 100% inhibition of SARS-CoV-2 virus infection at a very low antibody concentration experiment.

Sorrento is laser-focused to generate an antibody mixture product that would be a “protective shield" against SARS-CoV-2 Coronavirus infection and would be equally effective even if virus mutations render a single antibody therapy less effective over time.

Apparently, a dozen of these antibodies has thus far fared well showing the ability to block the S1 protein's interaction with human angiotensin-converting enzyme 2 (ACE2). Those blocking antibodies were further subjected to more refined testing for their ability to inhibit SARS-CoV-2 virus infection in an in vitro SARS-CoV-2 virus infection model pursuant to a preclinical testing agreement for COVID-19 therapeutic candidates.

One among the antibodies stood out for its ability to completely block SARS-CoV-2 infection of healthy cells during the experiments. STI-1499 can completely defuse the virus infectivity at a mare antibody dose. Preliminary biochemical and biophysical analyses also inferred that STI-1499 is a potentially potent antibody drug candidate.

This STI-1499 is determined to be the first antibody in the antibody cocktail (COVI-SHIELD™) it is developing. The antibody is assumed to be developed as a stand-alone therapy, (COVI-GUARD™) owing to the high potency it has exhibited in experiments to date. Sorrento plans to request an accelerated review from regulators to determine the best conduit to make any potential treatment available sooner. The company also seeks potential government support and pharmaceutical partners to further scale up STI-1499 manufacturing capacity aiming to potentially provide tens of millions of doses in less time to meet the vast projected demand.

 

Tags : #Coronavirus #Casualties #US #Antibody

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024